A population-based validation of the American Joint Committee on Cancer melanoma staging system
A population-based validation of the American Joint Committee on Cancer melanoma staging system
复制标题
DOI：
10.1200/jco.2005.02.4976
复制
发表时间：
2005-11-01
影响因子：
45.3
通讯作者：
Guerry, D
中科院分区：
文献类型：
--
作者：
Gimotty, PA;Botbyl, J;Guerry, D
目的2002年，美国癌症联合委员会（AJCC）对黑色素瘤分期进行了重大修订，该修订在包括来自癌症中心和合作团体的患者在内的多国队列中得到验证。该分期系统尚未在美国基于人群的队列中得到验证。患者和方法我们使用了1988年至2001年间从国家癌症研究所的监测、流行病学和最终结果（SEER）癌症登记处诊断的41，417名原发性侵袭性皮肤黑色素瘤患者来验证修订后的AJCC分期系统。将根据分期特异性Kaplan-Meier曲线计算的生存率（至黑色素瘤特异性死亡的时间）与原始AJCC验证研究中17，600例患者的生存率进行比较。
Purpose A major revision of the American Joint Committee on Cancer (AJCC) stages for melanoma was implemented in 2002 after its validation in multinational cohorts including patients from cancer centers and cooperative groups. This staging system has not been validated in a US population-based cohort.Patients and Methods We used 41,417 patients with primary invasive cutaneous melanoma diagnosed between 1988 and 2001 from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registry to validate the revised AJCC staging system. Survival rates computed from stage-specific Kaplan-Meier curves (time to melanoma-specific death) were compared with the survival rates from 17,600 patients in the original AJCC validation study.Results In the SEER cohort, 65% of reported melanomas were